TB-500 (thymosin beta-4 fragment)
Synthetic fragment of thymosin beta-4 studied preclinically for tissue repair.
Peptides
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
TB-500 (thymosin beta-4 fragment)
Synthetic fragment of thymosin beta-4 studied preclinically for tissue repair.
Evidence category: Preclinical. This describes the source category, not approval or certainty.
Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.
TB-500 is sold as thymosin beta-4 or a fragment of it; the owner's wiki warns that products may contain either. The wiki records it as a research chemical: the parent molecule reached late-stage trials as eye drops and earlier phases in other forms, but none of these are approved or marketed. The linked studies are animal and laboratory work, including a rat Achilles tendon study where TB-500 improved failure load and histology, and a mouse corneal wound study of an engineered variant. A scoping review of emerging sports peptides found most publications used animal models and noted missing efficacy and safety data in people.
Benefits reported in the imported source
- In a rat Achilles study it improved failure load and tendon histology against controls
Risks and limits
- A research chemical; the parent molecule reached trials but nothing is approved or marketed
- Products may contain thymosin beta-4 or only a fragment of it
- A scoping review found mostly animal work and missing efficacy and safety data in people
Source bottom line: An unapproved healing peptide with rat tendon results and no human efficacy or safety data.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
32 male Sprague-Dawley rats after Achilles tendon transection and repair, 8 per group
- Reported regimen
- TB-500 (synthetic thymosin beta-4) 60 µg/kg a day intraperitoneally, against control, BPC-157 and the two combined
- Duration
- four weeks after surgery
- Reported outcome
- The TB-500 group had significantly higher maximum load to failure and lower Bonar and Movin scores than controls; adding BPC-157 gave no further benefit.
- Source
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (Biçer et al. 2026)
Claim provenance
evidence.json#/catalog:peptide:tb-500/protocols/0
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — TB‑500 Dosage Guide: How Much Should You Take for Recovery and Injury
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: Swolverine's TB-500 dosage guide documents a loading phase of 4-8 mg per week split into 2 injections for weeks 1-4, followed by a maintenance phase of 2-6 mg per month (one injection every 1-2 weeks) for weeks 5-8 and beyond, with protocols varying by injury type from acute injuries at 6-8 mg weekly to chronic joint pain at 4-6 mg weekly.
TB‑500 Dosage Guide: How Much Should You Take for Recovery and Injury
Unverified imported account — The Wolverine Stack: Your Complete Guide to BPC-157 & TB-500 for Injury Healing
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: Community discussions on TB-500 for injury recovery report typical loading protocols of 2.0-2.5 mg administered twice per week (4-5 mg weekly total) for 4-6 weeks, followed by maintenance doses of 2 mg every 1-2 weeks as needed, with administration via subcutaneous injection noted as systemic regardless of injection site.
The Wolverine Stack: Your Complete Guide to BPC-157 & TB-500 for Injury Healing
Pharmacokinetic context
Historical half-life estimate: 48 hours. Thymosin beta-4 fragment; preclinical Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.
Source references
- Peptide Wiki: TB-500 (thymosin beta-4 fragment) (wiki-origin reference; not independent corroboration)
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (Biçer et al. 2026)
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine (Tewari et al. 2026)
- Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing (Nguyen et al. 2025)
- Thymosin β4 and Actin: Binding Modes, Biological Functions and Clinical Applications (Ying et al. 2023)
- PubMed: thymosin beta-4
Snapshot provenance
Source ID: catalog:peptide:tb-500. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.